OraSure Technologies Teams With The Reed For Hope Foundation, Singer/Songwriter/Actress Keri Hilson and Dr. Rachael Ross to Enc
26 Giugno 2013 - 3:10PM
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that it
has teamed up with The Reed For Hope Foundation and their new
ambassador, award-winning singer/songwriter/actress Keri Hilson,
and medical doctor and sexologist Dr. Rachael Ross, to encourage
individuals to get tested for HIV on National HIV Testing Day on
June 27th using the new OraQuick® In-Home HIV Test.
National HIV Testing Day is an annual observance created to
encourage Americans to get tested for the HIV virus. This year
marks the first observance of National HIV Testing Day when
consumers have the option of purchasing the OraQuick® In-Home HIV
Test – the only FDA-approved over-the-counter rapid HIV test, which
now empowers consumers to get tested with the same test used by
healthcare professionals.
OraQuick® In-Home HIV Test Educational Campaign Media
Tour
As part of its ongoing educational and awareness efforts,
OraSure has teamed up with The Reed For Hope Foundation and its
"Love Healthy" campaign which encourages loved ones to be healthy
and test for HIV.
The Reed For Hope Foundation (RFHF), which was founded by Emmy
Award Winning Casting Director Robi Reed, aims to raise awareness,
gather resources, and build alliances with other charities and
organizations in the fight to stop preventable diseases like HIV,
eliminate health disparities and inspire general wellness.
RFHF's Love Healthy Ambassador Keri Hilson and Dr. Rachael Ross
will be making media appearances in New York City on June 26th and
27th in support of the campaign. The tour is part of an
integrated marketing program that includes events, as well as
national and local radio, outdoor, television, print and digital
advertising.
"We are honored to be working with Ms. Hilton and Dr. Ross, The
Reed For Hope Foundation, and so many dedicated state and local
organizations to raise awareness of the importance of HIV testing,
and help reduce the fear and stigma often associated with testing,"
said Douglas A. Michels, President and Chief Executive Officer of
OraSure Technologies. "Now consumers have direct access to the
OraQuick In-Home HIV Test – the same test healthcare professionals
have used for years. They can now learn their HIV status in the
privacy of their own homes."
2013 National HIV Testing Day Consumer
Perception/Attitude Survey
OraSure also released the results from its "2013 National HIV
Testing Day Consumer Perception/Attitude Survey," which surveyed
1,000 sexually active adults on perception of risk for HIV and
common barriers to getting tested for HIV.
The survey found wide disparities between HIV risk perception
and behavior among the consumers surveyed, and underscored the need
for more education and awareness around HIV testing. More
information and key findings of the OraQuick National HIV Testing
Day Survey can be found at http://www.oraquick.com/media.
According to the Centers for Disease Control and Prevention
(CDC), there are approximately 1.2 million people in the U.S. that
have HIV and approximately 240,000 of them are unaware of their
status. Those who do not know they are HIV positive are
disproportionately responsible for the 50,000 new HIV infections
that occur each year.
Approved by the U.S. Food and Drug Administration (FDA) in July
2012, the OraQuick® In-Home HIV Test is the first rapid infectious
disease test ever to be made available directly to consumers for
in-home use. The OraQuick® In-Home Test was named one of the
"Best Inventions of 2012" by TIME and was also named a "Top Health
Breakthrough of 2012" by Men's Health magazine. The product is an
over-the-counter version of the OraQuick ADVANCE® Rapid HIV-1/2
Antibody Test, an oral swab rapid HIV test with more than 25
million units sold in the professional market, including doctors,
hospitals, clinics and other trained professionals.
To ensure optimal support for individuals using the OraQuick®
In-Home HIV Test, OraSure offers live support and comprehensive
referral services 24 hours a day, seven days a week, every day of
the year, through a toll-free support center and comprehensive
consumer website at www.oraquick.com. The OraQuick® Support Center
is staffed with highly trained, bi-lingual (English/Spanish)
representatives who are available by telephone at 866-436-6527 to
answer questions about HIV/AIDS and using and interpreting the
test. They also provide referrals to follow-up and care, and can
take orders for the OraQuick In-Home HIV Test. Additionally, the
product website provides access to resources and referral to
follow-up counseling, confirmatory testing and medical care.
For more information on the OraQuick® In-Home HIV Test, visit
www.OraQuick.com.
About OraSure Technologies
OraSure Technologies is a leader in the development, manufacture
and distribution of oral fluid diagnostic and collection devices
and other technologies designed to detect or diagnose critical
medical conditions. Its innovative products include rapid tests for
the detection of antibodies to HIV and HCV at the point of care and
testing solutions for detecting various drugs of abuse. In July
2012, the Company received approval from the U.S. Food and Drug
Administration for the Company's OraQuick® In-Home HIV Test for
sale directly to consumers in the over-the-counter (OTC) market -
making it the first and only rapid OTC HIV test approved in the
U.S. In addition, the Company is a leading provider of oral fluid
sample collection, stabilization and preparation products for
molecular diagnostic applications. OraSure's portfolio of products
is sold globally to various clinical laboratories, hospitals,
clinics, community-based organizations and other public health
organizations, research and academic institutions, distributors,
government agencies, physicians' offices, and commercial and
industrial entities. The Company's products enable healthcare
providers to deliver critical information to patients, empowering
them to make decisions to improve and protect their health.
For more information on OraSure Technologies, please visit
www.orasure.com.
CONTACT: Media Contact:
Jennifer Moritz
Zer0 to 5ive for OraSure Technologies
917-748-4006
jmoritz@0to5.com
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni OraSure Technologies (NASDAQ:OSUR)
Storico
Da Lug 2023 a Lug 2024